

September 2021



Message from the Chair

Dear Tumor Markers and Cancer Diagnostics Division Members,

Greetings!

With the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo only weeks away, AACC office continues to take every possible measure to ensure the attendee's safety. 2021 AACC Annual Scientific Meeting & Clinical Lab Expo will showcase the cutting-edge science and technology in laboratory medicine. While this is a good opportunity for the global laboratory medicine community comes together to meet and communicate, the health and well-being of our community remains the top priority. More health and safety information can be found from AACC website (<https://meeting.aacc.org/about/aacc-covid19-health-and-safety-plan>).

Due to the pandemic and travel restriction, many of our colleagues are unable to attend this annual meeting and thus, our annual division events won't take place as planned. I would like to take this opportunity to thank all the TMCD division board members and the division members for your hard work and support during the past year. Please try your best to join the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo whether in-person or virtually.

See more announcements below.

Stay safe and healthy!

Sincerely,
Qing Meng, PhD, DABCC, FAACC
Chair, Tumor Markers and Cancer Diagnostics Division of AACC

September 2021

PAST CHAIR AWARD

Congratulation on Dr. Lakshmi V. Ramanathan for the past chair award and for her outstanding contributions to the Tumor Markers and Cancer Diagnostics Division.

Dr. Lakshmi V. Ramanathan is the Service Chief of Clinical Chemistry in the Department of Laboratory Medicine at Memorial Sloan Kettering Cancer Center in New York City. She obtained her PhD in Nutritional Biochemistry and Metabolism at Massachusetts Institute of Technology in Cambridge, Massachusetts, USA. Her research interests include laboratory automation and biomarkers in cancer diagnostics. She is very active in the American Association of Clinical Chemistry. She was the past chair of the New York metro section, the Science Practice Core Committee of AACC and is currently a member of the Awards Committee and the AACC Global Quality Initiative Asia-Pacific Working Group. She served as the founding chair of AACC Tumor Markers and Cancer Diagnostics Division during 2017-20219.



BEST ABSTRACT AWARDS

This year, the Division has received many well-written, high caliber abstracts and the selection process was very competitive. Among those, two best abstracts were selected and the winners are Dr. DJ Sakrikar and Dr. David Barnidge. Please join me in congratulating them for their outstanding work and achievement.

426: Multi-Site Verification of the Automated EXENT® MALDI-TOF-MS System and Immunoglobulin Isotypes Assay for the Identification and Quantification of Monoclonal Immunoglobulins

Dr. DJ Sakrikar is the Mass Spectrometry Manager at The Binding Site's research and development laboratory in Rochester, MN. He is a mass spectrometrists with over a decade of experience using mass spectrometry to characterize and quantify proteins, lipids and metabolites. His most recent work has been in the area of monoclonal and polyclonal immunoglobulin characterization, quantification, and isotyping using LC-ESI-Q-TOF MS and MALDI-TOF MS. This

September 2021

methodology can be used to diagnose patients with B cell disorders such as multiple myeloma and amyloidosis as well as autoimmune disorders.



448: Comparison of the automated EXENT® MALDI TOF MS system for the qualitative assessment of monoclonal immunoglobulins in urine

Dr. David Barnidge the laboratory director at The Binding Site's research and development laboratory in Rochester, MN. He is a mass spectrometrists with over 25 years of experience using mass spectrometry to characterize and quantify proteins. He has been the lead author on influential papers demonstrating the ability of mass spectrometry to quantify proteins using proteotypic peptides and LC-MS/MS. His most recent work has been in the area of monoclonal and polyclonal immunoglobulin characterization, quantification, and isotyping using LC-ESI-Q-TOF MS and MALDI-TOF MS. This methodology can be used to diagnose patients with B cell disorders such as multiple myeloma and amyloidosis as well as autoimmune disorders.



JOINT DIVISION EVENT

TMCD will co-host a virtual presentation with Molecular Pathology and Personalized Medicine is going to happen after the Annual Meeting. Stay tuned.